Jacques J. M. van Dongen

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

Jacques J. M. van Dongen, Taku Seriu, E. Renate Panzer-Grümayer et al. · The Lancet · 1998 · 956 citations

Hematological Malignancy, Lymphoid Neoplasia, Acute Lymphoblastic Leukaemia +9

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Jacques J. M. van Dongen, Ludovic Lhermitte, Sebastian Böttcher et al. · Leukemia · 2012 · 893 citations · Full text

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer et al. · Journal of Clinical Oncology · 2001 · 882 citations

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

Emmanuel Beillard, Niels Pallisgaard, Vincent H. J. van der Velden et al. · Leukemia · 2003 · 879 citations

Hematological Malignancy, Polymerase Chain Reaction, Prognostic Biomarkers +11

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Valentino Conter, Claus R. Bartram, Maria Grazia Valsecchi et al. · Blood · 2010 · 778 citations · Full text